Omnicell, Inc. (NASDAQ:OMCL) Shares Purchased by XTX Topco Ltd

XTX Topco Ltd boosted its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 316.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 30,295 shares of the company’s stock after acquiring an additional 23,015 shares during the period. XTX Topco Ltd owned 0.06% of Omnicell worth $1,059,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Omnicell by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company’s stock worth $247,628,000 after purchasing an additional 28,573 shares in the last quarter. Victory Capital Management Inc. lifted its stake in Omnicell by 10.1% during the first quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company’s stock worth $58,745,000 after purchasing an additional 154,038 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Omnicell by 31.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company’s stock worth $73,127,000 after purchasing an additional 394,820 shares in the last quarter. Lazard Asset Management LLC lifted its stake in Omnicell by 81.6% during the fourth quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company’s stock worth $73,093,000 after purchasing an additional 737,536 shares in the last quarter. Finally, ArrowMark Colorado Holdings LLC lifted its stake in Omnicell by 4.9% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 1,196,990 shares of the company’s stock worth $53,290,000 after purchasing an additional 56,117 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Wells Fargo & Company upped their price target on Omnicell from $37.00 to $40.00 and gave the stock an “overweight” rating in a research note on Monday, July 21st. Piper Sandler reaffirmed an “overweight” rating on shares of Omnicell in a research report on Friday, May 23rd. Wall Street Zen raised Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 12th. Bank of America upped their price objective on Omnicell from $30.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, May 23rd. Finally, Benchmark cut their price objective on Omnicell from $62.00 to $40.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $45.33.

Omnicell Trading Down 4.0%

Shares of Omnicell stock opened at $29.76 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.23. Omnicell, Inc. has a 1 year low of $22.66 and a 1 year high of $55.74. The company has a market capitalization of $1.39 billion, a P/E ratio of 59.52, a P/E/G ratio of 8.69 and a beta of 0.77. The business has a 50 day moving average price of $29.27 and a 200 day moving average price of $33.11.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.15. Omnicell had a return on equity of 4.27% and a net margin of 2.01%. The firm had revenue of $290.56 million during the quarter, compared to the consensus estimate of $275.57 million. During the same period in the previous year, the firm posted $0.51 EPS. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. Sell-side analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.